Michael York, VP, Corporate Development at PhaseBio Pharmaceuticals Inc (PHAS), bought 1,500 shares at $3.88 ($6K) on 2018-12-11, disclosed to the SEC on 2018-12-11.
Open-market purchase of $6k PHAS by VP, Corporate Development. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.